Peace-of-Mind Program
A virtual diagnostic evaluation for autism may provide you with the peace of mind you deserve.
Virtual Autism Evaluation for ClearStrand-ASD Patients
LinusBio is providing support for ClearStrand-ASD patients to receive telehealth evaluations by independent autism specialists at no extra cost, in many cases.
This evaluation can help you feel confident that your child is not on the autism spectrum, or if your child is diagnosed with autism, it will provide you with a diagnostic report that is necessary to access autism-specific therapy they need.
After your child's ClearStrand-ASD result has been delivered, a LinusBio representative will contact you to help initiate the process if you are interested. You can also contact us to learn more.
How this offer works
- A. If your child lives in a state where LinusBio has a partnership with a telehealth organization providing autism evaluation services, your child may receive an evaluation by their specialists at no extra cost. Your child must be between the ages of 16 and 36 months at the time of the evaluation.
- B. If your child lives in a state where LinusBio does not have partners providing telehealth diagnostic evaluations, you may be eligible for a rebate up to $800 from LinusBio after the completion of an evaluation by an autism specialist of your choice, subject to our terms and conditions. The evaluation must be completed within two years after ClearStrand-ASD is purchased.
This special offer for a telehealth evaluation by an autism specialist is available after ClearStrand-ASD testing is complete, regardless of whether the child receives a negative or non-negative result.
If your child is under 16 months of age
Autism evaluations are not conducted by LinusBio partners before the child is 16 months of age. If your child gets ClearStrand-ASD testing before 16 months of age, they will still be eligible for an autism evaluation supported by the LinusBio Peace-of-Mind program when they turn 16 months.
Once the child turns 16 months, a LinusBio partner will reach out to you to schedule an evaluation with an autism specialist if you are in an eligible state.
If your child is not yet 16 months, or you are on a waitlist to be evaluated by your child’s provider, there are many resources available to better understand developmental milestones and options to intervene early. Your state’s early intervention program may be a good place to start.
Thank you for your request
Thank you! Your message has been sent successfully. We’ll get back to you within the next 3 business days.
Get support
Fill out the form for additional help
Or call us at 1-877-LinusBio (546-8724)
Message frequency may vary. You may opt out at any time. Terms and Conditions and Privacy Policy
Give your child the advantage of objective insights
Take a proactive step in supporting your child’s development and well-being with ClearStrand-ASD.
Page contents
Important information
ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) when it is a concern in children aged 1 month up to 36 months of age. It detects a biomarker associated with autism using a strand of hair. ClearStrand-ASD must be ordered by a licensed health care provider. Rx only. ClearStrand-ASD results can be negative or non-negative.
A child with a negative result is unlikely to be on the autism spectrum. A child with a non-negative result may need further autism diagnostic evaluation. ClearStrand-ASD is not a standalone diagnostic test. Health care providers should consider the test result in the context of other factors relevant to their clinical decision making. ClearStrand-ASD analyzes a strand of hair to map the dynamic patterns of an individual's unique biological response to environmental exposures over time at a molecular level and uses an algorithm to assess the likelihood of autism from the patterns. It is not a genetic test.
The test is performed by the LinusBio CLIA-certified laboratory (CLIA #31d2307499) and has not been cleared or approved by the US Food and Drug Administration (FDA).